Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTECT maintenance: long-term ABX464 25 mg or 50 mg once-daily vs placebo in moderate to severe ulcerative colitis
CTR20232946Phase 3Active
- Sponsor
- Abivax
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obefazimod in autoimmune colitis (3 arms), sponsored by Abivax. Primary endpoint: Proportion of subjects achieving clinical remission. Started Jun 2024; status: active.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20232946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232946.